Erica J Young
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$4.7MFederal grants as PI5 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
5 awards · $4.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 18, 2025 | NIH | SBIR Phase II Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2 | $1.5M | Myosin Therapeutics Inc. |
| Aug 9, 2023 | NIH | SBIR Phase II Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse | $1.2M | Myosin Therapeutics Inc. |
| Apr 14, 2023 | NIH | SBIR Phase II Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse | $441K | Myosin Therapeutics Inc. |
| Aug 11, 2022 | NIH | SBIR Phase II Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse | $1.2M | Myosin Therapeutics Inc. |
| Sep 21, 2021 | NIH | SBIR Phase II Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse | $325K | Myosin Therapeutics Inc. |
Peer ranks
Federal funding#300
Awards as PI#417
Patents#273
Companies
- Myosin Therapeutics Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.